BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 19276256)

  • 1. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX; Kakehi Y
    Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
    Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
    Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
    Jin X; Wu XX; Jin C; Inui M; Sugimoto M; Kakehi Y
    Anticancer Drugs; 2012 Apr; 23(4):445-54. PubMed ID: 22205156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
    Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
    J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L; Zhang X; Barrisford GW; Olumi AF
    Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
    Reddy RM; Tsai WS; Ziauddin MF; Zuo J; Cole GW; Maxhimer JB; Fang B; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):883-91. PubMed ID: 15573073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
    Ahmed SM; Wu X; Jin X; Zhang X; Togo Y; Suzuki T; Li Y; Kanematsu A; Nojima M; Yamamoto S; Sugimoto M; Kakehi Y
    Oncol Rep; 2015 Feb; 33(2):566-72. PubMed ID: 25483927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
    Zhang X; Li W; Olumi AF
    Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of Bid and Bax in indirubin-3'-monoxime-induced apoptosis in human cancer cells.
    Shi J; Shen HM
    Biochem Pharmacol; 2008 May; 75(9):1729-42. PubMed ID: 18377873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
    Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM; van der Zee AG; van den Heuvel FA; Timmer T; de Vries EG; de Jong S
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.